George Kouklakis Eleni I Efremidou Michael Pitiakoudis Nikolaos Liratzopoulos Alexandros Ch Polychronidis
10.2147/DDDT.S41889
Drug Des Devel Ther
2013;7:195-9.
adalimumab causal relationship melanocytic proliferation tumor necrosis factor alpha
NO-CC CODE
https://pubmed.ncbi.nlm.nih.gov/23569358/
Antibodies, Monoclonal, Humanized / adverse effects Antirheumatic Agents / adverse effects Melanoma / chemically induced Skin Neoplasms / chemically induced
Antibodies, Monoclonal, Humanized / adverse effects Antirheumatic Agents / adverse effects Melanoma / chemically induced Skin Neoplasms / chemically induced Case Reports Review Adalimumab Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / therapeutic use Antirheumatic Agents / administration & dosage Antirheumatic Agents / therapeutic use Crohn Disease / drug therapy Crohn Disease / pathology Female Humans Melanoma / pathology Middle Aged Severity of Illness Index Skin Neoplasms / pathology Time Factors Tumor Necrosis Factor-alpha / antagonists & inhibitors Antibodies, Monoclonal, Humanized Antirheumatic Agents Tumor Necrosis Factor-alpha Adalimumab
PMC3615922
23569358
Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer
2013